Reports

Sale

Europe Anti-Obesity Drugs Market Size, Share, Trends, Growth: By Drugs: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Others; By Drug Class; By Mechanism of Action; By Route of Administration; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Europe Anti-Obesity Drugs Market Outlook

The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of obesity. The global market is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.

Key Takeaways

In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. The rising prevalence of obesity is expected to drive market demand.

One of the major Europe anti-obesity drugs market trends is the increased investment in obesity drug production to reduce shortages and improve accessibility for weight loss medications. In November 2023, Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs, including Wegovy and Ozempic.

Expansion in production facilities is poised to address manufacturing needs and stimulate innovation in the anti-obesity drugs in the region. In November 2023, Eli Lilly and Company invested USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs including Mounjaro and Trulicity.

Europe Anti-Obesity Drugs Market Analysis

The market is witnessing steady growth driven by the increasing prevalence of obesity in the region. Various factors such as unhealthy eating habits, sedentary lifestyles, and certain genetic predispositions, among others, are resulting in the sharp growth of the bariatric population. In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. With the rising obesity prevalence, the Europe anti-obesity drugs market demand is likely to witness a surge owing to the efficacy of these medications in managing weight and reducing associated health risks.

One of the major market trends is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs. The funding will amplify the manufacturing capacity for Novo’s popular weight loss drugs, Wegovy and Ozempic, along with other obesity treatments under development. Such substantial investments are expected to reduce shortages and improve accessibility for weight loss medications, thereby propelling the Europe anti-obesity drugs market growth in the forecast period.

In November 2023, a similar investment initiative was taken by Eli Lilly and Company, intended to address the soaring demand for anti-obesity drugs in Europe. The company revealed its plan to invest USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs such as Mounjaro and Trulicity. The expansion of such production facilities in the region is poised to accommodate manufacturing needs and stimulate innovation in the obesity treatment segment, thereby fuelling market share.

Europe Anti-Obesity Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup	Categories
Drugs	Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide
Drug Class	Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor
Mechanism of Action	Centrally Acting Drugs, Peripherally Acting Drugs
Route of Administration	Oral, Subcutaneous
Prescription Type	Prescription Drugs, Over The Counter Drugs
Distribution Channel	Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies
Countries	United Kingdom, Germany, France, Italy, Others

Europe Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

VIVUS Inc

Pfizer, Inc.

Novo Nordisk

Bayer AG

F. Hoffmann-La Roche

Glaxosmithkline

Arena Pharmaceuticals

Eisai Co. Ltd

Takeda Pharmaceutical Company

Nalpropion Pharmaceuticals Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2017-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Drugs Drug Class Mechanism of Action Route of Administration Prescription Type Distribution Channel Region
Breakup by Drugs	Semaglutide Phentermine/Topiramate Naltrexone/Bupropion Liraglutide Gelesis 100 Orlistat Phentermine Methamphetamine Tirzepatide
Breakup by Drug Class	Amphetamine GLP-1 receptor agonist Lipase Inhibitor
Breakup by Mechanism of Action	Centrally Acting Drugs Peripherally Acting Drugs
Breakup by Route of Administration	Oral Subcutaneous
Breakup by Prescription Type	Prescription Drugs Over The Counter Drugs
Breakup by Distribution Channel	Hospital Pharmacies Drug Store & Retail Pharmacies Online Pharmacies
Breakup by Region	United Kingdom Germany France Italy Others
Market Dynamics	Market Drivers and Constraints SWOT Analysis Porter’s Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis
Supplier Landscape	Market Structure Company Profiles Financial Analysis Product Portfolio Demographic Reach and Achievements Mergers and Acquisitions Certifications
Companies Covered	VIVUS Inc Pfizer, Inc. Novo Nordisk Bayer AG F Hoffmann-La Roche Glaxosmithkline Arena Pharmaceuticals Eisai Co. Ltd Takeda Pharmaceutical Company Nalpropion Pharmaceuticals Inc

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Europe Anti-Obesity Drugs Market Overview
   3.1   Europe Anti-Obesity Drugs Market Historical Value (2017-2023)
   3.2   Europe Anti-Obesity Drugs Market Forecast Value (2024-2032)
4   Europe Anti-Obesity Drugs Market Landscape*
   4.1   Europe Anti-Obesity Drugs Market: Developers Landscape
       4.1.1   Analysis by Year of Establishment
       4.1.2   Analysis by Company Size
       4.1.3   Analysis by Region
   4.2   Europe Anti-Obesity Drugs Market: Product Landscape
       4.2.1   Analysis by Product
       4.2.2   Analysis by Material
       4.2.3   Analysis by Type
5   Europe Anti-Obesity Drugs Market Dynamics
   5.1   Market Drivers and Constraints
   5.2   SWOT Analysis
       5.2.1   Strengths
       5.2.2   Weaknesses
       5.2.3   Opportunities
       5.2.4   Threats
   5.3   Porter’s Five Forces Analysis
       5.3.1   Bargaining Power of Suppliers
       5.3.2   Bargaining Power of Buyers
       5.3.3   Threat of New Entrants
       5.3.4   Threat of Substitutes
       5.3.5   Degree of Rivalry
   5.4   Key Demand Indicators
       5.5   Key Price Indicators
       5.6   Industry Events, Initiatives, and Trends
       5.7   Value Chain Analysis
6   Europe Anti-Obesity Drugs Market Segmentation (2017-2032)
   6.1   Europe Anti-Obesity Drugs Market (2017-2032) by Drugs
       6.1.1   Market Overview
       6.1.2   Semaglutide
       6.1.3   Phentermine/Topiramate
       6.1.4   Naltrexone/Bupropion
       6.1.5   Liraglutide
       6.1.6   Gelesis 100
       6.1.7   Orlistat
       6.1.8   Phentermine
       6.1.9   Methamphetamine
       6.1.10   Tirzepatide
   6.2   Europe Anti-Obesity Drugs Market (2017-2032) by Drug Class
       6.2.1   Market Overview
       6.2.2   Amphetamine
       6.2.3   GLP-1 receptor agonist
       6.2.4   Lipase Inhibitor
   6.3   Europe Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
       6.3.1   Market Overview
       6.3.2   Centrally Acting Drugs
       6.3.3   Peripherally Acting Drugs
   6.4   Europe Anti-Obesity Drugs Market (2017-2032) by Route of Administration
       6.4.1   Market Overview
       6.4.2   Oral
       6.4.3   Subcutaneous
   6.5   Europe Anti-Obesity Drugs Market (2017-2032) by Prescription Type
       6.5.1   Market Overview
       6.5.2   Prescription Drugs
       6.5.3   Over The Counter Drugs
   6.6   Europe Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
       6.6.1   Market Overview
       6.6.2   Hospital Pharmacies
       6.6.3   Drug Store & Retail Pharmacies
       6.6.4   Online Pharmacies
   6.7   Europe Anti-Obesity Drugs Market (2017-2032) by Countries
       6.7.1   Market Overview
       6.7.2   United Kingdom
       6.7.3   Germany
       6.7.4   France
       6.7.5   Italy
       6.7.6   Others
7   United Kingdom Anti-Obesity Drugs Market (2017-2032)
   7.1   United Kingdom Anti-Obesity Drugs Market (2017-2032) By Drugs
       7.1.1   Market Overview
       7.1.2   Semaglutide
       7.1.3   Phentermine/Topiramate
       7.1.4   Naltrexone/Bupropion
       7.1.5   Liraglutide
       7.1.6   Gelesis 100
       7.1.7   Orlistat
       7.1.8   Phentermine
       7.1.9   Methamphetamine
       7.1.10   Tirzepatide
   7.2   United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Class
       7.2.1   Market Overview
       7.2.2   Market Overview
       7.2.3   Amphetamine
       7.2.4   GLP-1 receptor agonist
       7.2.5   Lipase Inhibitor
   7.3   United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
       7.3.1   Market Overview
       7.3.2   Centrally Acting Drugs
       7.3.3   Peripherally Acting Drugs
   7.4   United Kingdom Anti-Obesity Drugs Market (2017-2032) by Route of Administration
       7.4.1   Market Overview
       7.4.2   Oral
       7.4.3   Subcutaneous
   7.5   United Kingdom Anti-Obesity Drugs Market (2017-2032) by Prescription Type
       7.5.1   Market Overview
       7.5.2   Prescription Drugs
       7.5.3   Over The Counter Drugs
   7.6   United Kingdom Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
       7.6.1   Market Overview
       7.6.2   Hospital Pharmacies
       7.6.3   Drug Store & Retail Pharmacies
       7.6.4   Online Pharmacies
8   Germany Anti-Obesity Drugs Market (2017-2032)
   8.1   Germany Anti-Obesity Drugs Market (2017-2032) By Drugs
       8.1.1   Market Overview
       8.1.2   Semaglutide
       8.1.3   Phentermine/Topiramate
       8.1.4   Naltrexone/Bupropion
       8.1.5   Liraglutide
       8.1.6   Gelesis 100
       8.1.7   Orlistat
       8.1.8   Phentermine
       8.1.9   Methamphetamine
       8.1.10   Tirzepatide
   8.2   Germany Anti-Obesity Drugs Market (2017-2032) by Drug Class
       8.2.1   Market Overview
       8.2.2   Market Overview
       8.2.3   Amphetamine
       8.2.4   GLP-1 receptor agonist
       8.2.5   Lipase Inhibitor
   8.3   Germany Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
       8.3.1   Market Overview
       8.3.2   Centrally Acting Drugs
       8.3.3   Peripherally Acting Drugs
   8.4   Germany Anti-Obesity Drugs Market (2017-2032) by Route of Administration
       8.4.1   Market Overview
       8.4.2   Oral
       8.4.3   Subcutaneous
   8.5   Germany Anti-Obesity Drugs Market (2017-2032) by Prescription Type
       8.5.1   Market Overview
       8.5.2   Prescription Drugs
       8.5.3   Over The Counter Drugs
   8.6   Germany Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
       8.6.1   Market Overview
       8.6.2   Hospital Pharmacies
       8.6.3   Drug Store & Retail Pharmacies
       8.6.4   Online Pharmacies
9   France Anti-Obesity Drugs Market (2017-2032)
   9.1   France Anti-Obesity Drugs Market (2017-2032) By Drugs
       9.1.1   Market Overview
       9.1.2   Semaglutide
       9.1.3   Phentermine/Topiramate
       9.1.4   Naltrexone/Bupropion
       9.1.5   Liraglutide
       9.1.6   Gelesis 100
       9.1.7   Orlistat
       9.1.8   Phentermine
       9.1.9   Methamphetamine
       9.1.10   Tirzepatide
   9.2   France Anti-Obesity Drugs Market (2017-2032) by Drug Class
       9.2.1   Market Overview
       9.2.2   Market Overview
       9.2.3   Amphetamine
       9.2.4   GLP-1 receptor agonist
       9.2.5   Lipase Inhibitor
   9.3   France Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
       9.3.1   Market Overview
       9.3.2   Centrally Acting Drugs
       9.3.3   Peripherally Acting Drugs
   9.4   France Anti-Obesity Drugs Market (2017-2032) by Route of Administration
       9.4.1   Market Overview
       9.4.2   Oral
       9.4.3   Subcutaneous
   9.5   France Anti-Obesity Drugs Market (2017-2032) by Prescription Type
       9.5.1   Market Overview
       9.5.2   Prescription Drugs
       9.5.3   Over The Counter Drugs
   9.6   France Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
       9.6.1   Market Overview
       9.6.2   Hospital Pharmacies
       9.6.3   Drug Store & Retail Pharmacies
       9.6.4   Online Pharmacies
10   Italy Anti-Obesity Drugs Market (2017-2032)
   10.1   Italy Anti-Obesity Drugs Market (2017-2032) By Drugs
       10.1.1   Market Overview
       10.1.2   Semaglutide
       10.1.3   Phentermine/Topiramate
       10.1.4   Naltrexone/Bupropion
       10.1.5   Liraglutide
       10.1.6   Gelesis 100
       10.1.7   Orlistat
       10.1.8   Phentermine
       10.1.9   Methamphetamine
       10.1.10   Tirzepatide
   10.2   Italy Anti-Obesity Drugs Market (2017-2032) by Drug Class
       10.2.1   Market Overview
       10.2.2   Market Overview
       10.2.3   Amphetamine
       10.2.4   GLP-1 receptor agonist
       10.2.5   Lipase Inhibitor
   10.3   Italy Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
       10.3.1   Market Overview
       10.3.2   Centrally Acting Drugs
       10.3.3   Peripherally Acting Drugs
   10.4   Italy Anti-Obesity Drugs Market (2017-2032) by Route of Administration
       10.4.1   Market Overview
       10.4.2   Oral
       10.4.3   Subcutaneous
   10.5   Italy Anti-Obesity Drugs Market (2017-2032) by Prescription Type
       10.5.1   Market Overview
       10.5.2   Prescription Drugs
       10.5.3   Over The Counter Drugs
   10.6   Italy Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
       10.6.1   Market Overview
       10.6.2   Hospital Pharmacies
       10.6.3   Drug Store & Retail Pharmacies
       10.6.4   Online Pharmacies
11   Regulatory Framework
12   Patent Analysis
   12.1   Analysis by Type of Patent
   12.2   Analysis by Publication year
   12.3   Analysis by Issuing Authority
   12.4   Analysis by Patent Age
   12.5   Analysis by CPC Analysis
   12.6   Analysis by Patent Valuation
   12.7   Analysis by Key Players
13   Funding and Investment Analysis
   13.1   Analysis by Funding Instances
   13.2   Analysis by Type of Funding
   13.3   Analysis by Funding Amount
   13.4   Analysis by Leading Players
   13.5   Analysis by Leading Investors
   13.6   Analysis by Geography
14   Partnership and Collaborations Analysis
   14.1   Analysis by Partnership Instances
   14.2   Analysis by Type of Partnership
   14.3   Analysis by Leading Players
   14.4   Analysis by Geography
15   Supplier Landscape
   15.1   Market Share by Top 5 Companies
   15.2   VIVUS Inc
       15.2.1   Financial Analysis
       15.2.2   Product Portfolio
       15.2.3   Demographic Reach and Achievements
       15.2.4   Mergers and Acquisitions
       15.2.5   Certifications
   15.3   Pfizer, Inc.
       15.3.1   Financial Analysis
       15.3.2   Product Portfolio
       15.3.3   Demographic Reach and Achievements
       15.3.4   Mergers and Acquisitions
       15.3.5   Certifications
   15.4   Novo Nordisk
       15.4.1   Financial Analysis
       15.4.2   Product Portfolio
       15.4.3   Demographic Reach and Achievements
       15.4.4   Mergers and Acquisitions
       15.4.5   Certifications
   15.5   Bayer AG
       15.5.1   Financial Analysis
       15.5.2   Product Portfolio
       15.5.3   Demographic Reach and Achievements
       15.5.4   Mergers and Acquisitions
       15.5.5   Certifications
   15.6   F Hoffmann-La Roche
       15.6.1   Financial Analysis
       15.6.2   Product Portfolio
       15.6.3   Demographic Reach and Achievements
       15.6.4   Mergers and Acquisitions
       15.6.5   Certifications
   15.7   Glaxosmithkline
       15.7.1   Financial Analysis
       15.7.2   Product Portfolio
       15.7.3   Demographic Reach and Achievements
       15.7.4   Mergers and Acquisitions
       15.7.5   Certifications
   15.8   Arena Pharmaceuticals
       15.8.1   Financial Analysis
       15.8.2   Product Portfolio
       15.8.3   Demographic Reach and Achievements
       15.8.4   Mergers and Acquisitions
       15.8.5   Certifications
   15.9   Eisai Co. Ltd
       15.9.1   Financial Analysis
       15.9.2   Product Portfolio
       15.9.3   Demographic Reach and Achievements
       15.9.4   Mergers and Acquisitions
       15.9.5   Certifications
   15.10   Takeda Pharmaceutical Company
       15.10.1   Financial Analysis
       15.10.2   Product Portfolio
       15.10.3   Demographic Reach and Achievements
       15.10.4   Mergers and Acquisitions
       15.10.5   Certifications
   15.11   Nalpropion Pharmaceuticals Inc
       15.11.1   Financial Analysis
       15.11.2   Product Portfolio
       15.11.3   Demographic Reach and Achievements
       15.11.4   Mergers and Acquisitions
       15.11.5   Certifications
16   Europe Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
   16.1   Overview
   16.2   Potential Distributors
   16.3   Key Parameters for Distribution Partner Assessment
17   Key Opinion Leaders (KOL) Insights (Additional Insight)
18   Company Competitiveness Analysis (Additional Insight)
   18.1   Very Small Companies
   18.2   Small Companies
   18.3   Mid-Sized Companies
   18.4   Large Companies
   18.5   Very Large Companies
19   Payment Methods (Additional Insight)
   19.1   Government Funded
   19.2   Private Insurance
   19.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

What is the Europe anti-obesity drugs market forecast outlook for 2024-2032?

The Europe anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.70% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.

What are the major factors aiding the Europe anti-obesity drugs market demand?

The rising prevalence of obesity and heightened awareness about the health risks associated with obesity are fuelling the demand for the market.

What are the major Europe anti-obesity drugs market trends?

One of the significant trends in the market is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs.

What is the market segmentation based on the drugs?

Based on the drugs, the market is segmented into semaglutide, phentermine/topiramate, naltrexone/bupropion, liraglutide, gelesis 100, orlistat, phentermine, methamphetamine, and tirzepatide.

What are the various drug classes available in the market?

Drug classes available in the market include amphetamine, GLP-1 receptor agonist, and lipase inhibitors.

What is the market breakup by mechanism of action?

By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.

What is the market segmentation based on the route of administration?

The market breakup by route of administration includes oral and subcutaneous.

What is the market segmentation based on the prescription type?

The market breakup by prescription type includes prescription drugs and over the counter drugs.

What are the major distribution channels of anti-obesity drugs?

Distribution channels of the market are hospital pharmacies, drug store & retail pharmacies, and online pharmacies.

What is the market segmentation by countries?

The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.

Who are the key players involved in the Europe anti-obesity drugs market?

The key players in the market are VIVUS Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F. Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc.

Request Sample

Purchase Full Report

Mini Report

$ ~~2639~~ $2399

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~4399~~ $3999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~5829~~ $5299

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~6929~~ $6299

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER